Companies › Excyte Biopharma
2 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Genitourinary, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YK012 Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate | CD19, CD3 | Phase 1 | Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Dec 2026 |
| YKST02 BCMA-CD3 bispecific antibody | BCMA, CD3E | Phase 1 | Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06982729 | YK012 | Phase 1 | Primary Membranous Nephropathy | Genitourinary | Dec 2026 |
| NCT06580301 | YK012 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Oncology | Dec 2026 |
| NCT06574568 | YKST02 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Dec 2026 |
| NCT07010835 | YK012 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Jun 2027 |
| NCT06565689 | YK012 | Phase 1 | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.